Patents by Inventor Kelly Reed Clark

Kelly Reed Clark has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • GENE THERAPY FOR TREATING PROPIONIC ACIDEMIA
    Publication number: 20230129893
    Abstract: This present disclosure provides recombinant adeno-associated virus (rAAV) and methods of their use in gene therapy for treating propionic acidemia (PA). Also provided are pharmaceutical compositions comprising a rAAV of the invention and a pharmaceutically acceptable carrier or excipient. These pharmaceutical compositions may be useful in gene therapy for the treatment of PA caused by a mutation in propionyl-CoA carboxylase ?-subunit (PCCA) or a mutation in propionyl-CoA carboxylase ?-subunit (PCCB).
    Type: Application
    Filed: March 30, 2021
    Publication date: April 27, 2023
    Inventors: Matthew Scott Fuller, Samuel Wadsworth, Kelly Reed Clark, Sean Christopher Daugherty, Stewart Craig
  • Recombinant Adeno-Associated Virus Delivery of Alpha-Sarcoglycan Polynucleotides
    Publication number: 20220370639
    Abstract: The present invention relates to recombinant adeno-associated virus (rAAV) delivery of an alpha-sarcoglycan gene. The invention provides rAAV products and methods of using the rAAV in the treatment of limb girdle muscular dystrophies such as LGMD2D.
    Type: Application
    Filed: May 17, 2022
    Publication date: November 24, 2022
    Inventors: Jerry R. Mendell, Louis Chicoine, Louise Rodino-Klapac, Kelly Reed Clark, Thomas J. Preston
  • Recombinant adeno-associated virus delivery of alpha-sarcoglycan polynucleotides
    Patent number: 11446396
    Abstract: The present invention relates to recombinant adeno-associated virus (rAAV) delivery of an alpha-sarcoglycan gene. The invention provides rAAV products and methods of using the rAAV in the treatment of limb girdle muscular dystrophies such as LGMD2D.
    Type: Grant
    Filed: September 19, 2018
    Date of Patent: September 20, 2022
    Assignee: NATIONWIDE CHILDREN'S HOSPITAL, INC.
    Inventors: Jerry R. Mendell, Louis Chicoine, Louise Rodino-Klapac, Kelly Reed Clark, Thomas J. Preston
  • RECOMBINANT VIRUS PRODUCTS AND METHODS FOR INHIBITING EXPRESSION OF DYSTROPHIA MYOTONICA PROTEIN KINASE AND/OR INTERFERING WITH A TRINUCLEOTIDE REPEAT EXPANSION IN THE 3' UNTRANSLATED REGION OF THE DMPK GENE
    Publication number: 20220033823
    Abstract: The present disclosure relates to RNA interference-based methods for inhibiting the expression of the dystrophia myotonia protein kinase (DMPK) gene. Recombinant adeno-associated viruses of the disclosure deliver DNAs encoding inhibitory RNAs that knock down the expression of DMPK or interfere with the expression of the CTG repeat associated with myotonic dystrophy type-1 (DM1). The methods have application in the treatment of myotonic dystrophies, including DM1, and other disorders associated with aberrant DMPK expression.
    Type: Application
    Filed: August 22, 2019
    Publication date: February 3, 2022
    Inventors: Nicolas Sebastien Wein, Scott Quenton Harper, Kelly Reed Clark
  • METHODS AND COMPOSITIONS FOR TREATING GLYCOGEN STORAGE DISEASES
    Publication number: 20220017922
    Abstract: This invention provides a variety of novel adeno-associated vims (AAV) vectors for gene therapy applications in the treatment of glycogen storage disease type 1a (GSD-Ia). Disclosed herein are a number of recombinant nucleic acid molecules, vectors and recombinant AAV that incorporate a modified G6PC promoter/enhancer sequence. Utilization of the modified G6PC promoter/enhancer sequence results in enhanced AAV yield and quality when expressed from various host cell platforms. Also provided herein are compositions comprising the novel AAV of the invention and methods of treating GSD-Ia using the same.
    Type: Application
    Filed: December 18, 2019
    Publication date: January 20, 2022
    Inventors: Christopher Tipper, Kelly Reed Clark, Samuel Wadsworth
  • GENE THERAPY FOR TREATING PROPIONIC ACIDEMIA
    Publication number: 20210283272
    Abstract: This present disclosure provides adeno-associated viral vectors, recombinant adeno-associated virus (rAAV), and methods of their use in gene therapy for treating propionic acidemia (PA). Also provided are pharmaceutical compositions comprising a recombinant adeno-associated virus of the invention and a pharmaceutically acceptable carrier or excipient. These pharmaceutical (compositions may be useful in gene therapy for the treatment of PA caused by mutations in propionyl-CoA carboxylase ?-subunit (PCCA) or mutations in propionyl-CoA carboxylase ?-subunit (PCCB).
    Type: Application
    Filed: October 1, 2019
    Publication date: September 16, 2021
    Inventors: Matthew Scott Fuller, Samuel Wadsworth, Kelly Reed Clark, Sean Christopher Daugherty, Stewart Craig
  • METHODS FOR ENHANCING YIELD OF RECOMBINANT ADENO-ASSOCIATED VIRUS
    Publication number: 20200048641
    Abstract: The invention provides methods for the production of recombinant adeno-associated virus vectors (rAAV), e.g., comprising the addition of a surfactant, e.g., Triton X-100, to a producer cell culture medium.
    Type: Application
    Filed: March 22, 2018
    Publication date: February 13, 2020
    Inventors: Ying Jing, Jan Panteli, Kelly Reed Clark
  • USE OF GLUCOCORTICOID ANALOGS TO ENHANCE RECOMBINANT ADENO-ASSOCIATED VIRUS YIELD
    Publication number: 20190290710
    Abstract: The invention provides methods for the production of recombinant adeno-associated virus vectors (rAAV), comprising contacting a host cell with a solution comprising a glucocorticoid analog, such as dexamethasone. Also provided are methods for increasing the production of rAAV by a host cell, comprising contacting a host cell with a solution comprising a glucocorticoid analog, such as dexamethasone.
    Type: Application
    Filed: July 12, 2017
    Publication date: September 26, 2019
    Inventors: Ying Jing, Mingyang Jiang, Kelly Reed Clark
  • RECOMBINANT ADENO-ASSOCIATED VIRUS DELIVERY OF ALPHA-SARCOGLYCAN POLYNUCLEOTIDES
    Publication number: 20190000998
    Abstract: The present invention relates to recombinant adeno-associated virus (rAAV) delivery of an alpha-sarcoglycan gene. The invention provides rAAV products and methods of using the rAAV in the treatment of limb girdle muscular dystrophies such as LGMD2D.
    Type: Application
    Filed: September 19, 2018
    Publication date: January 3, 2019
    Inventors: Jerry R. Mendell, Louis Chicoine, Louise Rodino-Klapac, Kelly Reed Clark, Thomas J. Preston
  • Recombinant adeno-associated virus delivery of alpha-sarcoglycan polynucleotides
    Patent number: 10105453
    Abstract: The present invention relates to recombinant adeno-associated virus (rAAV) delivery of an alpha-sarcoglycan gene. The invention provides rAAV products and methods of using the rAAV in the treatment of limb girdle muscular dystrophies such as LGMD2D.
    Type: Grant
    Filed: September 2, 2016
    Date of Patent: October 23, 2018
    Assignee: NATIONWIDE CHILDREN'S HOSPITAL, INC.
    Inventors: Jerry R. Mendell, Louis Chicoine, Louise Rodino-Klapac, Kelly Reed Clark, Thomas J. Preston
  • RECOMBINANT ADENO-ASSOCIATED VIRUS DELIVERY OF ALPHA-SARCOGLYCAN POLYNUCLEOTIDES
    Publication number: 20170209598
    Abstract: The present invention relates to recombinant adeno-associated virus (rAAV) delivery of an alpha-sarcoglycan gene. The invention provides rAAV products and methods of using the rAAV in the treatment of limb girdle muscular dystrophies such as LGMD2D.
    Type: Application
    Filed: September 2, 2016
    Publication date: July 27, 2017
    Inventors: Jerry R. Mendell, Louis Chicoine, Louise Rodino-Klapac, Kelly Reed Clark, Thomas J. Preston
  • Recombinant adeno-associated virus delivery of alpha-sarcoglycan polynucleotides
    Patent number: 9434928
    Abstract: The present invention relates to recombinant adeno-associated virus (rAAV) delivery of an alpha-sarcoglycan gene. The invention provides rAAV products and methods of using the rAAV in the treatment of limb girdle muscular dystrophies such as LGMD2D.
    Type: Grant
    Filed: November 21, 2012
    Date of Patent: September 6, 2016
    Assignee: NATIONWIDE CHILDREN'S HOSPITAL, INC.
    Inventors: Jerry R. Mendell, Louis Chicoine, Louise Rodino-Klapac, Kelly Reed Clark, Thomas J. Preston
  • EXPRESSION OF VIRUS ENTRY INHIBITORS AND RECOMBINANT AAV THEREFOR
    Publication number: 20150044170
    Abstract: The present invention relates generally to the use of recombinant adeno-associated viruses (rAAV) for gene delivery and more specifically to the use of rAAV to deliver genes encoding human immunodeficiency virus entry inhibitors to target cells in mammals.
    Type: Application
    Filed: April 9, 2014
    Publication date: February 12, 2015
    Applicant: NATIONWIDE CHILDREN'S HOSPITAL, INC.
    Inventors: Philip R. Johnson, JR., Kelly Reed Clark
  • RECOMBINANT ADENO-ASSOCIATED VIRUS DELIVERY OF ALPHA-SARCOGLYCAN POLYNUCLEOTIDES
    Publication number: 20140323956
    Abstract: The present invention relates to recombinant adeno-associated virus (rAAV) delivery of an alpha-sarcoglycan gene. The invention provides rAAV products and methods of using the rAAV in the treatment of limb girdle muscular dystrophies such as LGMD2D.
    Type: Application
    Filed: November 21, 2012
    Publication date: October 30, 2014
    Inventors: Jerry R. Mendell, Louis Chicoine, Louise Rodino-Klapac, Kelly Reed Clark, Thomas J. Preston
  • Recombinant adeno-associated virus production
    Patent number: 8409842
    Abstract: The present invention relates to methods and materials for recombinant adeno-associated virus production. More particularly, the invention relates to use of recombinant adenovirus encoding adeno-associated virus protein in recombinant adeno-associated virus production methods.
    Type: Grant
    Filed: March 18, 2009
    Date of Patent: April 2, 2013
    Assignee: Nationwide Children's Hospital, Inc.
    Inventors: Kelly Reed Clark, Philip R. Johnson, Jr.
  • EXPRESSION OF VIRUS ENTRY INHIBITORS AND RECOMBINANT AAV THEREFOR
    Publication number: 20120171160
    Abstract: The present invention relates generally to the use of recombinant adeno-associated viruses (rAAV) for gene delivery and more specifically to the use of rAAV to deliver genes encoding human immunodeficiency virus entry inhibitors to target cells in mammals.
    Type: Application
    Filed: February 6, 2012
    Publication date: July 5, 2012
    Applicant: NATIONWIDE CHILDREN'S HOSPITAL, INC.
    Inventors: Philip R. Johnson, JR., Kelly Reed Clark
  • ANTIBODY GENE TRANSFER AND RECOMBINANT AAV THEREFOR
    Publication number: 20120027798
    Abstract: The present invention relates generally to the use of recombinant adeno-associated viruses (rAAV) for gene delivery and more specifically to the use of rAAV to deliver antibody genes to target cells in mammals. Administration of rAAV encoding antibodies that neutralize the HIV-1 virus is exemplified.
    Type: Application
    Filed: July 6, 2011
    Publication date: February 2, 2012
    Applicant: NATIONWIDE CHILDREN'S HOSPITAL, INC.
    Inventors: Kelly Reed Clark, Philip R. Johnson, JR.
  • Recombinant Adeno-Associated Virus Production
    Publication number: 20090291503
    Abstract: The present invention relates to methods and materials for recombinant adeno-associated virus production. More particularly, the invention relates to use of recombinant adenovirus encoding adeno-associated virus protein in recombinant adeno-associated virus production methods.
    Type: Application
    Filed: March 18, 2009
    Publication date: November 26, 2009
    Applicant: NATIONWIDE CHILDREN'S HOSPITAL
    Inventors: Kelly Reed Clark, Philip Rudolph Johnson, JR.
  • Expression of virus entry inhibitors and recombinant AAV therefor
    Publication number: 20090169513
    Abstract: The present invention relates generally to the use of recombinant adeno-associated viruses (rAAV) for gene delivery and more specifically to the use of rAAV to deliver genes encoding human immunodeficiency virus entry inhibitors to target cells in mammals.
    Type: Application
    Filed: March 24, 2008
    Publication date: July 2, 2009
    Applicant: NATIONWIDE CHILDREN'S HOSPITAL
    Inventors: Philip R. Johnson, JR., Kelly Reed Clark
  • Recombinant adeno-associated virus production
    Patent number: 7510872
    Abstract: The present invention relates to methods and materials for recombinant adeno-associated virus production. More particularly, the invention relates to use of recombinant adenovirus encoding adeno-associated virus protein in recombinant adeno-associated virus production methods.
    Type: Grant
    Filed: February 26, 2004
    Date of Patent: March 31, 2009
    Assignee: Nationwide Children's Hospital
    Inventors: Kelly Reed Clark, Philip Rudolph Johnson, Jr.